Chimeric antigen receptor (CAR) T cell therapy has emerged as a groundbreaking treatment for relapsed/refractory B cell lymphomas, yet a significant proportion of patients fail to achieve durable responses. The tumor microenvironment (TME) and its inflammatory circuits play a pivotal role in shaping disease biology and therapeutic outcomes. 

Here, we aim to dissect the immunosuppressive features of the TME, with a particular focus on the STING signaling pathway, which we have identified as a potential key mediator of pro-inflammatory responses. 

Our goal is to identify novel strategies that enhance CAR T cell efficacy and overcome resistance in aggressive B cell lymphoma patients.

https://innere1.uk-koeln.de/forschung/arbeitsgruppen-labore/krebstherapie-und-molekulare-bildgebung/